Photo by satheeshsankaran from unsplash
At present, the absence of a pharmacological neuroprotectant represents an important unmet clinical need in the treatment of ischemic and traumatic brain injury. Recent evidence suggests that administration of apolipoprotein… Click to show full abstract
At present, the absence of a pharmacological neuroprotectant represents an important unmet clinical need in the treatment of ischemic and traumatic brain injury. Recent evidence suggests that administration of apolipoprotein E mimetic therapies represent a viable therapeutic strategy in this setting. We investigate the neuroprotective and anti‐inflammatory properties of the apolipoprotein E mimetic pentapeptide, CN‐105, in a microglial cell line and murine model of ischemic stroke.
Keywords:
apolipoprotein mimetic;
ischemic stroke;
peptide 105;
mimetic peptide;
105 improves
Journal Title: Annals of Clinical and Translational Neurology
Year Published: 2017
Link to full text (if available)
Share on Social Media: Sign Up to like & get
recommendations!
Journal Title: Annals of Clinical and Translational Neurology
Year Published: 2017
Link to full text (if available)
Share on Social Media: Sign Up to like & get
recommendations!